Research programme: Micacide protein therapeutics - Xyphos

Drug Profile

Research programme: Micacide protein therapeutics - Xyphos

Alternative Names: MICA-fusion proteins; Micacide™ proteins

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AvidBiotics Corp.
  • Developer Xyphos
  • Class Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Viral infections

Most Recent Events

  • 01 Nov 2017 AvidBiotics splits itself into two companies, Xyphos to Develop Cell-based Therapeutics for Cancer and Pylum Biosciences that will focus on antibacterial proteins for microbiota management and drug-resistant bacteria
  • 10 Sep 2013 Preclinical trials in Cancer in USA (Parenteral)
  • 10 Sep 2013 Preclinical trials in Viral infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top